中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Viral Diseases
Cancer
Exploratory Indications
Products&Pipeline
Pipeline
Products
Clinical Trials
Partnership
Investors
Financials & Filing
News
Careers
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Show More
2014
Ascletis Accredited as “One of China’s Top Ten Innovative Companies in 2019”
2019-12-07
Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout
2019-11-29
Ascletis to Present at the 17th Annual Morgan Stanley Asia Pacific Summit
2019-11-26
Dr. Jinzi Wu was Selected as the 10th Science and Technology New Zhejiang Merchants
2019-11-08
Manuscript Publication of the First All-oral DAA HCV Regimen Developed by Ascletis from China in the Journal of Clinical and Translational Hepatology
2019-10-21
Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer
2019-10-08
Dr. Jinzi J. Wu to Attend The Fortune Global Sustainability Forum 2019
2019-09-04
Ascletis Received IND Approval for its NASH Drug
2019-08-28
Ascletis Opens Clinical Development Shanghai Center
2019-08-12
Ascletis’ Strategic Partner 3-V Biosciences Announced its Name Change and Financing Status
2019-08-06
1
2
3
»